Skip to main content

Table 2 Levels of CEL and antigen binding to mAb 103-E3 determined in all investigated cohorts.

From: Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis

  RA versus SLE versus HC RA versus OA
  RA SLE HC RA OA
Equivalents of CEL-crystallin
(μg/ml)
4.87 ±
1.989
2.92 ±
1.140
2.83 ±
1.437
5.413 ± 2.631 2.994 ± 2.023
Equivalents of Rib-BSA (μg/ml) 3.306 ± 0.755 2.287 ± 0.675 2.111 ± 0.620 2.993 ± 0.668 1.873 ± 0.692
  1. RA - rheumatoid arthritis; SLE - systemic lupus erythematosus; OA - osteoarthritis; HC - healthy volunteers (controls). Results are expressed as means ± standard deviation of equivalents of CEL-crystallin or Rib-BSA. Samples with the level of measured antigen below the detection limit of the assay were not included in the calculation; these were 1 RA, 5 SLE, and 7 HC samples, respectively, assayed for CEL in the part "RA versus SLE versus HC", and 19 OA samples assayed for CEL and 1 OA sample assayed for 103-E3 antigen in the part "RA versus OA".